Bipolar Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 115
Price: $ 3500


GlobalData, the industry analysis specialist, has released its new report, “Bipolar Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global bipolar disorder market. The report identifies the key trends shaping and driving the global bipolar disorder market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global bipolar disorder sector. This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global bipolar disorder therapeutics market was valued at $6,242m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2.0% over the next eight years, to reach $7,340m by 2018. Atypical antipsychotics, mood stabilizers, and antidepressants are the commonly prescribed drugs for the treatment of bipolar disorder. The slow market growth during the forecast period is attributed to the patent expiry of leading drugs, the entry of new drugs, and stable prevalence. The bipolar disorder therapeutics market will witness the patent expiry of leading drugs such as Zyprexa (2011 in the US and Europe, 2015 in Japan), Seroquel (2012), Geodon/Zeldox (2012), Abilify (2014 in Europe, 2015 in the US and 2017 in Japan), and Sapharis/Sycrest (2015). In addition to this, pipeline molecules such as cariprazine, Nuvigil (armodafinil), and Latuda (lurasidone hydrochloride) are expected to be launched in 2013. GlobalData expects that these factors will account for positive growth within the bipolar disorder therapeutics market through 2018.

During 2000-2005, several drugs were approved for the treatment of bipolar disorder, such as Abilify (aripiprazole), Geodon/Zeldox (ziprasidone), Lamictal (lamotrigine), Risperdal (risperidone), Seroquel (quetiapine), Symbyax (olanzapine and fluoxetine combination) and Zyprexa (olanzapine). Increased uptake of these approved drugs resulted in a relatively high growth of the market through the historic period 2005-2010.

Browse All: Pharmaceuticals Market Research

Scope
The report provides information on the key drivers and challenges of the bipolar disorder market. Its scope includes -
- Annualized data on seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) for bipolar disorder revenue from 2005 to 2010, with forecasts to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed, and emerging trends. Pipeline candidates fall under major therapeutic classes such as dopamine and serotonin receptor antagonist, selective serotonin reuptake inhibitor (SSRI), sodium channel blocker, N-methyl D-aspartate (NMDA) receptor antagonist, partial agonist at dopamine and serotonin receptor, dopamine D3/D2 partial agonist, analeptic activity, ion channel blocker, selective serotonin reuptake enhancer, NMDA Receptor modulator, muscarinic receptor antagonist, deoxyribonucleic acid (DNA) polymerase inhibitor, microglial activation inhibitor, xanthine oxidase inhibitor, ion channel blocker and NMDA antagonist, opoid antagonist, glutamate inhibitor, mood stabilizer, acting on depression and anxiety related central nervous system (CNS) receptors, anti-psychotic, and stimulating the release of norepinephrine.
- Analysis of the current and future competition in the global bipolar disorder market. Key market players covered are Alexza Pharmaceuticals, Gedeon Richter, Dainippon Sumitomo Pharma and Cephalon.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the bipolar disorder therapeutics market.
- Analysis of key recent licensing and partnership agreements in the bipolar disorder market.

Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global bipolar disorder market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global bipolar disorder market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global bipolar disorder market landscape? – Identify, understand and capitalize.